Pembrolizumab berahyaluronidase alfa vs Sintilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Sintilimab

Marketed by Innovent Biologics and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03607539 · Phase 3 · completed

This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.

Next expected readout: November 2026 · NCT05429463 (registry estimate)

Reported efficacy

Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)

Result source: NCT03150875

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPembrolizumab berahyaluronidase alfaSintilimab
PFS, median—Trial running · NCT057220158.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results
OS, median—Trial running · NCT0572201511.8 vs 8.3vs Docetaxeln 145NCT03150875
ORR64.3% vs 18.2%vs Pembrolizumabn 28NCT0621275251.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875
Duration of response, median—Trial running · NCT057220156.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result

PFS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Sintilimab
8.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results

OS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Sintilimab
11.8 vs 8.3vs Docetaxeln 145NCT03150875

ORR

Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Sintilimab
51.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875

Duration of response, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Sintilimab
6.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumab berahyaluronidase alfaSintilimab
Dropout rate
n/a: no completion milestonea
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestonea
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
n/a: no completion milestone
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—a
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
—
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
39%a
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
28.2%a
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
38.9%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
50.3%
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
a
anaemia 74.1% (placebo 78.6%)
neutrophil count decreased 71.1% (placebo 62.6%)
white blood cell count decreased 67.7% (placebo 64.1%)
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
anaemia 33.3%
decreased appetite 23.6%
pyrexia 21.5%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
anaemia 93.3% (placebo 90.4%)
white blood cell count decreased 88.8% (placebo 86%)
neutrophil count decreased 83.2% (placebo 82%)
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sintilimab

PFS 8.9 vs 5 placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
4.3 vs 2.79 Docetaxel months
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
5.5 vs 4.9 placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Overall Survival NA vs NA placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
11.79 vs 8.25 Docetaxel months
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
NA vs NA placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Disease Control 86.8% (n=266) vs 75.6% (n=131) placebo
responder rate · % of participants
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
86% (n=179) vs 80.3% (n=178) placebo
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Time to Response 1.51 vs 2.63 placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
1.41 vs 1.41 placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Duration of Response NA vs 5.52 placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
12.45 vs 4.14 Docetaxel months
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.05 vs 5.06 placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Sintilimab's landscape